VIP and PACAP: Novel approaches to brain functions and neuroprotection

Current Pharmaceutical Design

Volumn 17, Issue 10, 2011, Pages 961-

  Shioda, Seiji ^a   Gozes, Illana ^b  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; DAVUNETIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; MESSENGER RNA; PHOSPHOLIPASE C; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ADRENAL GLAND; ALZHEIMER DISEASE; ARTERIAL PRESSURE; BRAIN FUNCTION; CIRCADIAN RHYTHM; DIAGNOSTIC ERROR; DRUG MECHANISM; EDITORIAL; EPILEPSY; EXCITOTOXICITY; GASTROINTESTINAL TRACT; HOMEOSTASIS; HYPOPHYSIS; IMMUNE RESPONSE; LIVER; NERVE CELL DIFFERENTIATION; NERVE INJURY; NEUROPROTECTION; NONHUMAN; PAIN; PANCREAS; PARKINSON DISEASE; PERIPHERAL NERVOUS SYSTEM; PLEIOTROPY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RECEPTOR AFFINITY; RNA SPLICING; SCHIZOPHRENIA; THYROID GLAND;

ANIMALS; BRAIN; HUMANS; NEUROPROTECTIVE AGENTS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; VASOACTIVE INTESTINAL PEPTIDE;

EID: 79958121938     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211795589391     Document Type: Editorial

References (14)

1. Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science 1970; 169: 1217-8.
2. Said SI, Mutt V. Isolation from porcine-intestinal wall of a vasoactive octapeptide related to secretin and to glucagon. Eur J Biochem 1972; 28: 199-204.
3. Miyata A, Arimura A, Dahl RD, Minamino N, Uehara A, Jinang L, Culler MD, Coy DH. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 1989; 164: 567-74.
4. Bassan M, Zamostiano R, Davidson A, Pinhasov A, Gialdndi E, Perl O, Bassan H, Blat C, Gibney G, Glaznr G, Brenneman DE, Gozes I. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 1999; 72: 1283-93.
5. Gozes, I. NAP (Davunetide) provides functional and structural neuroprotection. Curr Pharm Des 2011; 1040-44.
6. Shioda S, Wascheck JA. Type II Family of GPCRs-VIP & PACAP receptors. pp 527-545 In Understanding G-Protein-coupled Receptors and their Role in the CNS. Edit by Pangalos MN and Davises CH. Oxford University Press 2002.
7. Gozes I. VIP-PACAP 2010: My own perspectives on modulation of cognitive and emotional behavior. J Mol Neurosci 2010; 42: 261-3.
8. Reglodi D, Kiss P, Lubics A, Tamas A. Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo. Curr Pharm Des 2011; 17(10): 962-72.
9. Nakamachi T, Farkas J, Watanabe J, Ohtaki H, Dohi K, Arata S, Shioda S. Role of PACAP in neural stem cell/projenitor cell and astorcyte-from neural development to neual repair. Curr Pharm Des 2011; 17(10): 973-84.
10. Hashimoto H, Shintani N, Tanida M, Hayata A, Hashimoto R, Baba A. PACAP is implicated in the stress axes. Curr Pharm Des 2011; 17(10): 985-89.
11. Pinhasov A, Nesher E, Gross M, Turgeman G, Kreinin A, Yadid G. The role of the PACAP signaling sytem in depression. Curr Pharm Des 2011; 17(10): 990-1001.
12. Bourgault S, Chatenet D, Wurts O, Doan ND, Leprince J, Vaudry H, Fournier A, Vaudry D. Strategies to convert PACAP from a hypophysiotropic neurohormone into a neuroprotective drug. Curr Phar Des 2011; 17(10): 1002-24.
13. Abad C, Wascheck JA. Immunomodulatory roles of VIP and PACAP in models of multiple sclerosis. Curr Pharm Des 2011; 17(10): 1025-35.
14. Passmard S, Sokolowska P, Schwendimann L, Gressens P. VIP-induced neuroprotection of the developing brain. Curr Pharm Des 2011; 17(10): 1036-